Opinion|Videos|November 27, 2024
Managing Treatment Challenges in HER2-Directed Therapies
Key Takeaways
- Understanding molecular mechanisms of resistance is crucial for developing novel therapeutic agents and combination strategies in HER2-directed therapies.
- Personalized medicine, utilizing genomic profiling, is expected to tailor treatments to individual patient profiles, enhancing efficacy.
An exploration of emerging strategies to overcome resistance to HER2-directed therapies based on ongoing research advancements.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How might strategies to address resistance to HER2-directed therapies evolve with ongoing research?
Advertisement
Related to this article
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.
At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
Advertisement
Advertisement
Trending on AJMC
1
At the Pharmacy, Affordability Connects Policy, Plans, and Patients
2
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia
3
UAB Works to Deliver Cutting-Edge Cancer Therapies, Reach Every Patient
4
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
5